Mineralys Therapeutics (MLYS) Cash & Current Investments (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Cash & Current Investments data on file, last reported at $644.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 88.02% year-over-year to $644.9 million; the trailing twelve-month figure through Mar 2026 stood at $644.9 million (up 88.02% YoY), and the FY2025 full-year result was $656.6 million, up 231.32% from the prior year.
• Cash & Current Investments eased to $644.9 million in Q1 2026, from $656.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $656.6 million in Q4 2025 to a low of $110.1 million in Q4 2022.
• A 5-year average of $342.4 million and a median of $289.4 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slipped 16.22% in 2024 and soared 231.32% in 2025, its largest moves.
• Tracing MLYS's Cash & Current Investments over 5 years: stood at $110.1 million in 2022, then jumped by 114.85% to $236.6 million in 2023, then decreased by 16.22% to $198.2 million in 2024, then soared by 231.32% to $656.6 million in 2025, then dropped by 1.78% to $644.9 million in 2026.
• Business Quant data shows MLYS's Cash & Current Investments at $644.9 million in Q1 2026, $656.6 million in Q4 2025, and $593.6 million in Q3 2025.